Expression of progesterone receptors in meningioma patients: serial case

Yulia Damayanti; Dessika Rahmawati

doi:10.30574/gscbps.202013.2.0330

Authors

Yulia Damayanti Neurology Department, Faculty Medicine, Brawijaya University, Malang, Indonesia.
Dessika Rahmawati Neurooncology Consultant and Lecturers of Neurology Department, Faculty of Medicine, Brawijaya University, Malang, Indonesia.

DOI:

https://doi.org/10.30574/gscbps.202013.2.0330

Keywords:

Meningioma, Resection, Progesterone Receptor

Abstract

Meningioma is a tumor that arises from the meningothelial cells of the arachnoid membranes which are attached to the dura mater. Meningioma is one of the most common tumors found in people and occurs more commonly in women due to the link with the progesterone hormones. The risk of developing meningiomas is increased in patients who are exposed to exogenous progesterone such as hormonal contraceptives. This case report must be reported because the hormonal contraceptives are largely used in Indonesia and it is important to report this case. It is reported in three cases of female patients aged 58 years, 46 years, and 38 years with the main complaint of chronic progressive headache and decreased consciousness with left hemiparesis. All patients had a history of using hormonal contraceptives for more than four years. Head CT scans were carried out and obtained the results of extra-axial masses in the supratentorial region of all three patients. Therapeutic management was performed by resection with the result of immunohistochemistry of the three patients showing an expression of progesterone receptor > 90% in the tumor cell nucleus. Progesterone receptors were found in patients with meningioma. The expression of progesterone receptors on tumor cell nuclei is related to prognosis. A positive progesterone receptor will be adopted with a better prognosis. Hormonal therapy such as antiprogesterone can inhibit the genetic mutation of meningioma. Yet, it is not recommended because there is no significant clinical evidence.

Metrics

Metrics Loading ...

References

Sari EDY, Windarti I, and Wahyuni A. (2014). Clinical Characteristics and Histopathology of Brain Tumor at Two Hospitals in Bandar Lampung. Bosnian Journal Of Basic Medical Sciences, 48-56.

Aman AR, Soenarya FM, Andriani R. (2018). National Guidelines for Brain Tumor Medical Services. National Cancer Management Committee.

Rejeki SD, Agus S, and Syafrita Y. (2019). Relationship of Progesterone Receptor Expression and Ki-67 Labeling Index with Meningioma Histopathological Degrees. Pathology Magazine, 28: 7-13.

Aninditha T, Andriani R, and Malueka GR. (2019). Meningioma, Other Meningeal Tumors. Neurooncology Textbook. Indonesian Medicine, Jakarta, 115-129.

Wrensch M and Wiemels J. (2010). Epidemiology and etiology of meningioma. Journal of Neuroooncology, 99: 307-314.

Iplikcioglu CA, Hatiboglu AM, and Ozek E. (2014). Is progesterone receptor status really a prognostic factor for intracranial meningioma ? Clinical Neurology and Neurosurgery, 124: 119-122.

Kuroi Y, Matsumoto K, and Shibuya M. (2018). Progesterone Receptor is Responsible for Benign Biology of Skull Base Meningioma. World Neurosurgery, 7: e1-e7.

Ghasimi S, Haapasalo H, and Eray M. (2012). Immunohistochemical analysis of LRIG proteins in meningioma: correlation between estrogen receptor status and LRIG expression. Journal of Neurooncology, 108: 435-441.

Hua L, Zhu H, and Li J. (2017). Prognostic value of estrogen receptor in WHO Grade III meningioma: a long-term follow-up study from a single institution. Journal of Neurosurgery, 1-9.

Prasetyo E, Sadhana U, and Astuti MDK. (2017). Differences in Expression of p53 and PR (Progesterone Receptor) in Meninigoma Grade I, II, III at Dr. Kariadi. Young Medika Media, 2: 173-178.

Fakhrjou A, Meshkini A, Shadrvan S. Status of Ki-67, estrogen and progesterone receptors in various subtypes of intracranial meningiomas. Pakistan J Biol Sci. 2012; 15: 530-5.

Tessa AH, Jacob LF, and Monica D. (2017). Progesterone-only contraception is associated with shorter progression-free survival in premenopausal women with WHO Grade I Meningioma. Journal Neurooncology, 1-7.

Agus S, Muhammad BS, and Datu R. (2019). Relationships Between Neurofibromatosis-2, Progesterone Receptor Expression, the Use of Exogenous Progesterone, and Risk of Orbitocranial Meningioma in Females. Frontiers in Oncology, 8: 1-7.

Maria DML and Luiz AC. (2020). Treatment of a Woman with Inoperable Meningioma Using Mifepristone for 26 Years. Case Report in Neurological Medicine, 1-8.

Giulia C, Marc L, and Roy TD. (2015). The Role of Mifepristone in Meningiomas Management: A Systematic Revie of the Literature. BioMed Research International, 1-11.